This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioReference Laboratories, Inc. Announces Strategic Acquisition Of Edge BioSystems' Service Business

ELMWOOD PARK, N.J., Aug. 21, 2013 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc. (Nasdaq:BRLI) announced today that it has entered into a definitive agreement for the acquisition of Edge BioSystems CLIA laboratory business and related assets ("Edge BioServ"), primarily a genetic sequencing service business located in Gaithersburg, MD.

GeneDx, BRLI's wholly-owned clinical diagnostic sequencing laboratory, will acquire the Edge BioServ genetic sequencing services business, which service has been offered to a national list of customers. The acquisition will include sequencing equipment and capabilities that are expected to enhance the ability of GeneDx to maintain and improve its position as a premier provider of clinical genetic sequencing services. GeneDx is one of the leading full service genetic laboratories in the world and the Company believes the additional capacity and technical expertise that will result from this acquisition will greatly enhance the opportunity for further growth and expansion of the GeneDx service offerings. The acquisition will provide GeneDx with additional equipment on multiple testing platforms operating in a CLIA-certified environment as well as additional infrastructure for R&D initiatives. Dean Gaalaas, CEO of EdgeBio, will assume the position of COO at GeneDx, and will bring with him many of the talented R&D personnel, including experienced bioinformatics developers.

Marc D. Grodman, MD, CEO, commented: "Our GeneDx genetics laboratory is growing rapidly in a very sophisticated and complex area of laboratory medicine and we believe the Edge BioServ acquisition will enable us to have instant expandability for that growth. We have new lines of specialty work being developed, including our upcoming inherited cancers and tumor sequencing programs that we believe will be in great demand. The Edge BioServ acquisition is expected to enable us to seamlessly meet those demands. We believe this acquisition will substantially improve our national presence and our technological leadership. We believe that our existing genetics capabilities have made GeneDx a superior genetics sequencing laboratory and we expect the Edge BioServ acquisition will provide depth and capability to further enhance our premier status."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs